Related references
Note: Only part of the references are listed.Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
Danny Boerrigter et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015
Kamil E. Barbour et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)
Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study
Stephen A. Metcalf et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications
B. S. Fernandes et al.
MOLECULAR PSYCHIATRY (2016)
Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume
S. G. Fillman et al.
MOLECULAR PSYCHIATRY (2016)
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Erik Johnsen et al.
BMC PSYCHIATRY (2016)
Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior
R. Barzilay et al.
EUROPEAN PSYCHIATRY (2016)
Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset
Ewa Bulzacka et al.
SCHIZOPHRENIA BULLETIN (2016)
Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia
Burak Kulaksizoglu et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2016)
What's Hot in Schizophrenia Research?
Cynthia Shannon Weickert et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2016)
Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia
David W. Volk et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk
Tyrone D. Cannon et al.
BIOLOGICAL PSYCHIATRY (2015)
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
T. W. Weickert et al.
MOLECULAR PSYCHIATRY (2015)
Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project
Diana O. Perkins et al.
SCHIZOPHRENIA BULLETIN (2015)
A Nationwide Study on the Risk of Autoimmune Diseases in Individuals With a Personal or a Family History of Schizophrenia and Related Psychosis
Michael E. Benros et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Immune System Disturbances in Schizophrenia
Szatmar Horvath et al.
BIOLOGICAL PSYCHIATRY (2014)
First-Episode Psychosis: An Inflammatory State?
Zuzanna Zajkowska et al.
NEUROIMMUNOMODULATION (2014)
Immunology of Schizophrenia
Norbert Mueller
NEUROIMMUNOMODULATION (2014)
Role of C-reactive protein in schizophrenia: An overview
Bisu Singh et al.
PSYCHIATRY RESEARCH (2014)
Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses
Brian J. Miller et al.
BRAIN BEHAVIOR AND IMMUNITY (2013)
Biomarkers in Schizophrenia: A Brief Conceptual Consideration
Cynthia S. Weickert et al.
DISEASE MARKERS (2013)
C-reactive protein and substance use disorders in adolescence and early adulthood: A prospective analysis
E. Jane Costello et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Correlation between high-sensitivity C-reactive protein and brain gray matter volume in healthy elderly subjects
Yasuyuki Taki et al.
HUMAN BRAIN MAPPING (2013)
Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Sinead M. Gibney et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2013)
Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia
S. G. Fillman et al.
MOLECULAR PSYCHIATRY (2013)
C-reactive protein is related to memory and medial temporal brain volume in older adults
Brianne Magouirk Bettcher et al.
BRAIN BEHAVIOR AND IMMUNITY (2012)
Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study
Shaw-Ji Chen et al.
BRITISH JOURNAL OF PSYCHIATRY (2012)
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Imran B. Chaudhry et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages
Rodrigo Barbachan Mansur et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2012)
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Brian J. Miller et al.
BIOLOGICAL PSYCHIATRY (2011)
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Alan S. Brown et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Systemic Inflammation Is Associated with MCI and Its Subtypes: The Sydney Memory and Aging Study
Julian N. Trollor et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2010)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial
Wijnand Laan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
Jonathan M. Meyer et al.
BIOLOGICAL PSYCHIATRY (2009)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. Ridker et al.
LANCET (2009)
Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review
Stephane Potvin et al.
BIOLOGICAL PSYCHIATRY (2008)
Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents
Jennifer O'Loughlin et al.
NICOTINE & TOBACCO RESEARCH (2008)
C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children
David Gozal et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
Faith Dickerson et al.
SCHIZOPHRENIA RESEARCH (2007)
Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
Xiaoduo Fan et al.
PSYCHIATRY RESEARCH (2007)
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients
S Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease
John Gunstad et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2006)
The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample
JD Henry et al.
BRITISH JOURNAL OF CLINICAL PSYCHOLOGY (2005)
Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment
P Libby et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Complexity of prefrontal cortical dysfunction in schizophrenia: More than up or down
JH Callicott et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Inflammatory markers and cognition in well-functioning African-American and white elders
K Yaffe et al.
NEUROLOGY (2003)
Chlorpromazine equivalent doses for the newer atypical antipsychotics
SW Woods
JOURNAL OF CLINICAL PSYCHIATRY (2003)
C-reactive protein: a critical update
MB Pepys et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia
N Müller et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Cytokine profiles in schizophrenic patients treated with risperidone - A 3-month follow-up study
CL Cazzullo et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population - Jichi Medical School Cohort Study
S Yamada et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2001)
Self-report quality of life measure for people with schizophrenia: the SQLS
G Wilkinson et al.
BRITISH JOURNAL OF PSYCHIATRY (2000)
Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff?
MF Green et al.
SCHIZOPHRENIA BULLETIN (2000)
Share Paper
